Avenacy debuts generic Precedex
Avenacy, a specialty pharmaceutical company that supplies critical injectable medications, launched dexmedetomidine injection, a generic of Orion’s Precedex.
Dexmedetomidine injection is an alpha2-adrenergic receptor agonist indicated for:
- Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Dexmedetomidine Injection should be administered by continuous infusion not to exceed 24 hours.
- Sedation of non-intubated adult patients before and/or during surgical and other procedures.
[Read more: Avenacy intros generic Reglan]
Avenacy's dexmedetomidine injection is available as 200 mcg (base) per 2 ml (100 mcg (base) per ml) single-dose vials, with 25 vials per carton. In line with Avenacy’s mission to champion patient safety and streamline patient care, Dexmedetomidine Injection, USP will feature the company’s highly differentiated packaging and labeling to support accurate medication selection.
The company said it is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP-standards.
Dexmedetomidine injection had a market value of approximately $19 million for the 12 months ending September 2024, per IQVIA.
[Read more: Avenacy releases magnesium sulfate in water for injection]